1. A compound represented by the following structural formula:
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein:
Y is C(O), O, S, S(O), or S(O)2;
X1, X2, and X3 are each, independently, N or CR, provided that at least one of
X1, X2, or X3 is CR;
R for each occurrence and R1 are each, independently, H or a substituent;
R6 is H, an aliphatic carbonyl group, or an aliphatic ester;
ring A is substituted or unsubstituted; and
Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl.
2. The compound of claim 1, wherein Ar2 is phenyl, naphthyl, thienyl, or thianaphthenyl, each group being substituted or unsubstituted.
3. The compound of claim 1, wherein Ar1 is phenyl, pyridyl, pyrimidinyl, or pyrazinyl, each group being substituted or unsubstituted.
4. The compound of claim 1, which is represented by the following structural formula:
or a pharmaceutically acceptable salts, solvates, or hydrates thereof,
wherein: Y is S, O, S(O), or S(O)2;
R19 and R20 are each, independently, H or a substituent.
5. The compound of claim 1, which is represented by the following structural formula:
or pharmaceutically acceptable salts, solvates, or hydrates thereof,
wherein: R1, R2, R3, R4, R5, and each R are, independently, H, an aliphatic group, haloalkyl, halo, COOH, NO2, alkoxy, or haloalkoxy; and
X4 is CR, N or N+\u2014O\u2014.
6. The compound of claim 1 which is represented by the following structural formula:
or pharmaceutically acceptable salts, solvates, or hydrates thereof,
wherein:
X4 is CR, N or N+\u2014O\u2014;
R8 is H or an electron withdrawing group;
m and n are each, independently, 0 or an integer from 1 to 3;
each R9 is, independently, aliphatic, group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, hydroxy, NR11CO2R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R11)2, or NR11C(O)R12; or two adjacent R9 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R10 is, independently, halo, an aliphatic group, alkoxy, or haloalkyl; or two adjacent R10 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R11 is, independently, H or an aliphatic group; and
R12 is an aliphatic group.
7. The compound of claim 1 wherein the compound is represented by the following structural formula:
or pharmaceutically acceptable salts, solvates, or hydrates thereof,
wherein:
ring B is substituted or unsubstituted;
p is 0 or an integer from 1-3; and
each R13 is, independently, a halo or a substituted or unsubstituted heteroaryl.
8. A compound selected from the group consisting of:
N-4-Chloro-2-(2-chloro-benzoyl)-phenyl-4-nitro-benzenesulfonamide
Thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-(2-Benzoyl-4-chloro-phenyl)-4-iodo-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-chloro-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-tert-butyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-propyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-methoxy-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-isopropyl-benzenesulfonamide
4-Ethyl-N-4-nitro-2-(3-trifluoromethyl-benzoyl)-phenyl-benzenesulfonamide
N-4-Chloro-2-(3-methyl-benzoyl)-phenyl-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-chloro-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-ethoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-propoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-isopropoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-butoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-benzyloxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-phenoxy-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridine-4-carbonyl)-phenyl-4-ethoxy-benzenesulfonamide
N-4-Chloro-2-(pyridine-4-carbonyl)-phenyl-4-isopropyl-benzenesulfonamide
N-4-Chloro-2-(pyridine-4-carbonyl)-phenyl-4-isobutyl-benzenesulfonamide
N-5-Chloro-3-(pyridine-4-carbonyl)-pyridin-2-yl-4-ethoxy-benzenesulfonamide
N-5-Chloro-3-(pyridine-4-carbonyl)-pyridin-2-yl-4-isopropoxy-benzenesulfonamide
N-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-chloro-benzenesulfonamide
5-Benzoyl-6-(4-isopropoxy-benzenesulfonylamino)-nicotinic acid
N-(2-Benzoyl-4-chloro-phenyl)-2-nitro-benzenesulfonamide
N-(3-Benzoyl-5-nitro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-(5-Benzoyl-pyrimidin-4-yl)-4-isopropoxy-benzenesulfonamide
N-(3-Benzoyl-5-trifluoromethoxy-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-(5-Benzoyl-2-trifluoromethyl-pyrimidin-4-yl)-4-isopropoxy-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopropoxy-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclobutyl-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-tert-butoxy-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopentyl-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropylsulfanyl-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropylamino-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopropyl-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclohexyl-benzenesulfonamide
N-(3-Benzenesulfinyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-(3-Benzenesulfonyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyrimidine-5-carbonyl)-phenyl-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridazine-4-carbonyl)-phenyl-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(2-trifluoromethyl-pyrimidine-5-carbonyl)-phenyl-4-isopropoxy-
benzenesulfonamide
N-4-Chloro-2-(6-trifluoromethyl-pyridazine-4-carbonyl)-phenyl-4-isopropoxy-
benzenesulfonamide
N-4-Chloro-2-(2-trifluoromethyl-pyrimidine-5-carbonyl)-phenyl-4-isopropoxy-
benzenesulfonamide
N-4-Chloro-2-(6-trifluoromethyl-pyridazine-4-carbonyl)-phenyl-4-isopropoxy-
benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-isopropoxy-benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-methoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-trifluoromethoxy-benzenesulfonamide
5-Oxazol-5-yl-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-4-Chloro-2-(3-chloro-benzoyl)-phenyl-4-methoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-methoxy-benzenesulfonamide
N-4-Chloro-2-(3-chloro-benzoyl)-phenyl-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-ethylamino-benzenesulfonamide
5-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonic acid (2-benzoyl-
4-chloro-phenyl)-amide
N-(2-Benzoyl-4-iodo-phenyl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(3-fluoro-benzoyl)-phenyl-4-methyl-benzenesulfonamide
N-4-Chloro-2-(3-chloro-benzoyl)-phenyl-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-nitro-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-diethylamino-benzenesulfonamide
N-(2-Benzoyl-4-fluoro-phenyl)-4-methoxy-benzenesulfonamide
4-Chloro-N-4-chloro-2-(pyridine-3-carbonyl)-phenyl-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-methyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-bromo-benzenesulfonamide
N-4-Chloro-2-(pyridine-3-carbonyl)-phenyl-4-methoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-dimethylamino-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-fluoro-benzenesulfonamide
4-Chloro-N-4-chloro-2-(2-fluoro-benzoyl)-phenyl-benzenesulfonamide
N-4-Chloro-2-(2-fluoro-benzoyl)-phenyl-4-methoxy-benzenesulfonamide
Thiophene-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
5-Bromo-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
5-Chloro-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-4-Chloro-2-(2-fluoro-benzoyl)-phenyl-4-nitro-benzenesulfonamide
N-4-Chloro-2-(2-fluoro-benzoyl)-phenyl-4-methyl-benzenesulfonamide
4-Chloro-N-4-chloro-2-(pyridine-2-carbonyl)-phenyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-benzenesulfonamide
N-4-(2-Benzoyl-4-chloro-phenylsulfamoyl)-phenyl-acetamide
N-4-Chloro-2-(pyridine-2-carbonyl)-phenyl-4-methoxy-benzenesulfonamide
N-4-Chloro-2-(pyridine-2-carbonyl)-phenyl-4-methyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-cyano-benzenesulfonamide
4,5-Dibromo-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-4-Chloro-2-(pyridine-3-sulfonyl)-phenyl-4-nitro-benzenesulfonamide
Naphthalene-2-sulfonic acid 4-chloro-2-(pyridine-3-carbonyl)-phenyl-amide
N-(2-Benzoyl-4-chloro-phenyl)-3-bromo-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-methyl-3-nitro-benzenesulfonamide
N-4-Chloro-2-(2-methoxy-benzoyl)-phenyl-4-nitro-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-2-trifluoromethyl-benzenesulfonamide
5-Chloro-3-methyl-benzobthiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-
amide
N-(2-Benzoyl-phenyl)-4-nitro-benzenesulfonamide
5-Isoxazol-3-yl-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-(2-Benzoyl-phenyl)-4-methyl-benzenesulfonamide
Benzobthiophene-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-(4-Chloro-2-phenylsulfanyl-phenyl)-4-isopropoxy-benzenesulfonamide
N-(2-Benzenesulfonyl-4-chloro-phenyl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridine-4-carbonyl)-phenyl-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl-4-isopropoxy-benzenesulfonamide
4-Isopropoxy-N-2-(pyridine-4-carbonyl)-4-trifluoromethyl-phenyl-
benzenesulfonamide
4-Ethoxy-N-2-(pyridine-4-carbonyl)-4-trifluoromethyl-phenyl-benzenesulfonamide
N-5-Chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl-4-isopropyl-benzenesulfonamide
N-5-Chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl-4-isopropoxy-benzenesulfonamide
N-5-Chloro-3-(thiophene-2-carbonyl)-pyridin-2-yl-4-isopropoxy-benzenesulfonamide
5-Oxazol-5-yl-thiophene-2-sulfonic acid 5-chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl-
amide
N-3-(Benzofuran-2-carbonyl)-5-chloro-pyridin-2-yl-4-isopropoxy-
benzenesulfonamide
N-(2-Benzoyl-4-trifluoromethyl-phenyl)-4-isopropoxy-benzenesulfonamide
N-(3-Benzoyl-pyridin-4-yl)-4-isopropoxy-benzenes
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropyl-benzenesulfonamide
N-(3-Benzoyl-5-nitro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
5-Oxazol-5-yl-thiophene-2-sulfonic acid (3-benzoyl-5-chloro-pyridin-2-yl)-amide
N-(2-Benzoyl-4-chloro-phenyl)-4-isopropylamino-benzenesulfonamide
N-(4-Benzoyl-pyridin-3-yl)-4-isopropyl-benzenesulfonamide
N-(4-Benzoyl-pyridin-3-yl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridin-3-yloxy)-phenyl-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-pyridin-3-yl)-4-isopropoxy-benzenesulfonamide
N-3-(3-Fluoro-benzoyl)-pyridin-2-yl-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridin-3-yloxy)-phenyl-4-isopropoxy-benzenesulfonamide
4-Isopropoxy-N-3-(pyridine-4-carbonyl)-pyridin-4-yl-benzenesulfonamide
6-Isopropoxy-pyridine-3-sulfonic acid (3-benzoyl-5-chloro-pyridin-2-yl)-amide
6-Isopropoxy-pyridine-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-4-Chloro-2-(pyridin-2-ylsulfanyl)-phenyl-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-phenyl)-4-isopropoxy-benzenesulfonamide; and pharmaceutically
acceptable salts, solvates, and hydrates thereof.
9. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and the compound of claim 1.
10. A method of inhibiting a CCR9 receptor function in a subject in need thereof, comprising the step of administering to the subject an effective amount of a compound represented by the following structural formula:
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein:
Y is C(O), S, O, S(O) or S(O)2;
X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR;
R, for each occurrence, and R1 are each, independently, H or a substituent;
R6 is H, an aliphatic carbonyl group, or an aliphatic ester; and
ring A is substituted or unsubstituted;
Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
11. The method of claim 10, wherein the compound is represented by a structural formula selected from the group consisting of A, B, C, and D:
A.
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein: R19 and R20 are each, independently, H or a substituent;
B.
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein: R1, R2, R3, R4, R5, and each R are, independently, H, an aliphatic group, haloalkyl, a halo, COOH, NO2, alkoxy, or haloalkoxy; and
X4 is CR, N or N+\u2014O\u2212;
C.
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
X4 is CR, N or N+\u2014O\u2212;
R8 is H or an electron withdrawing group;
m and n are each, independently, 0 or an integer from 1 to 3;
each R9 is, independently, an aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, hydroxy, NR11CO2R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R11)2, or NR11C(O)R12; or two adjacent R9 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R10 is, independently, halo, aliphatic group, alkoxy, or haloalkyl; or two adjacent R10 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R11 is, independently, H or an aliphatic group; and
R12 is an aliphatic group; and
D.
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein:
R8 is halo, nitro, alkylcarbonyl or trihaloalkyl;
p is 0 or an integer from 1 to 3; and
each R13 is, independently, a halo, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heteroaryl.
12. The method of claim 10 wherein the subject is being treated for an inflammatory disease or condition.
13. A method of treating or preventing an inflammatory disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following structural formula:
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein:
Y is C(O), S, O, S(O) or S(O)2;
X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR;
R, for each occurrence, and R1 are each, independently, H or a substituent; and
ring A is substituted or unsubstituted;
R6 is H, an aliphatic group, an aryl group or an aliphatic carbonyl group; and
Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
14. The method of claim 13, wherein the compound is represented by a structural formula selected from the group consisting of A, B, C, and D:
A.
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein: R19 and R20 are each, independently, H or a substituent.
B.
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein: R1, R2, R3, R4, R5, and each R are, independently, H, an aliphatic group, haloalkyl, halo, COOH, NO2, alkoxy, or haloalkoxy; and
X4 is CR, N or N+\u2014O\u2212;
C.
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
X4 is CR, N or N+\u2014O\u2212;
R8 is H or an electron withdrawing group;
m and n are each, independently, 0 or an integer from 1 to 3;
each R9 is, independently, aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, hydroxy, NR11CO2R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R11)2, or NR11C(O)R12; or two adjacent R9 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R10 is, independently, halo, aliphatic group, alkoxy, or haloalkyl; or two adjacent R10 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R11 is, independently, H or an aliphatic group; and
R12 is an aliphatic group; and
D.
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein:
R8 is a halo, nitro, alkylcarbonyl or trihaloalkyl;
p is 0 or an integer from 1 to 3; and
each R13 is, independently, a halo, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heteroaryl.
15. The method of claim 13, wherein the compound is selected from the group consisting of:
N-4-Chloro-2-(2-chloro-benzoyl)-phenyl-4-nitro-benzenesulfonamide
Thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-(2-Benzoyl-4-chloro-phenyl)-4-iodo-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-chloro-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-tert-butyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-propyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-methoxy-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-isopropyl-benzenesulfonamide
4-Ethyl-N-4-nitro-2-(3-trifluoromethyl-benzoyl)-phenyl-benzenesulfonamide
N-4-Chloro-2-(3-methyl-benzoyl)-phenyl-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-chloro-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-ethoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-propoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-isopropoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-butoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-benzyloxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-phenoxy-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridine-4-carbonyl)-phenyl-4-ethoxy-benzenesulfonamide
N-4-Chloro-2-(pyridine-4-carbonyl)-phenyl-4-isopropyl-benzenesulfonamide
N-4-Chloro-2-(pyridine-4-carbonyl)-phenyl-4-isobutyl-benzenesulfonamide
N-5-Chloro-3-(pyridine-4-carbonyl)-pyridin-2-yl-4-ethoxy-benzenesulfonamide
N-5-Chloro-3-(pyridine-4-carbonyl)-pyridin-2-yl-4-isopropoxy-benzenesulfonamide
N-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-chloro-benzenesulfonamide
5-Benzoyl-6-(4-isopropoxy-benzenesulfonylamino)-nicotinic acid
N-(2-Benzoyl-4-chloro-phenyl)-2-nitro-benzenesulfonamide
N-(3-Benzoyl-5-nitro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-(5-Benzoyl-pyrimidin-4-yl)-4-isopropoxy-benzenesulfonamide
N-(3-Benzoyl-5-trifluoromethoxy-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-(5-Benzoyl-2-trifluoromethyl-pyrimidin-4-yl)-4-isopropoxy-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopropoxy-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclobutyl-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-tert-butoxy-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopentyl-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropylsulfanyl-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropylamino-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopropyl-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclohexyl-benzenesulfonamide
N-(3-Benzenesulfinyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-(3-Benzenesulfonyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyrimidine-5-carbonyl)-phenyl-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridazine-4-carbonyl)-phenyl-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(2-trifluoromethyl-pyrimidine-5-carbonyl)-phenyl-4-isopropoxy-
benzenesulfonamide
N-4-Chloro-2-(6-trifluoromethyl-pyridazine-4-carbonyl)-phenyl-4-isopropoxy-
benzenesulfonamide
N-4-Chloro-2-(2-trifluoromethyl-pyrimidine-5-carbonyl)-phenyl-4-isopropoxy-
benzenesulfonamide
N-4-Chloro-2-(6-trifluoromethyl-pyridazine-4-carbonyl)-phenyl-4-isopropoxy-
benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-isopropoxy-benzenesulfonamide
N-(2-Benzoyl-4-nitro-phenyl)-4-methoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-trifluoromethoxy-benzenesulfonamide
5-Oxazol-5-yl-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-4-Chloro-2-(3-chloro-benzoyl)-phenyl-4-methoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-methoxy-benzenesulfonamide
N-4-Chloro-2-(3-chloro-benzoyl)-phenyl-4-ethyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-ethylamino-benzenesulfonamide
5-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonic acid (2-benzoyl-4-
chloro-phenyl)-amide
N-(2-Benzoyl-4-iodo-phenyl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(3-fluoro-benzoyl)-phenyl-4-methyl-benzenesulfonamide
N-4-Chloro-2-(3-chloro-benzoyl)-phenyl-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-nitro-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-diethylamino-benzenesulfonamide
N-(2-Benzoyl-4-fluoro-phenyl)-4-methoxy-benzenesulfonamide
4-Chloro-N-4-chloro-2-(pyridine-3-carbonyl)-phenyl-benzenesulfonamide
N-(2-Benzoyl-4-bromo-phenyl)-4-methyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-bromo-benzenesulfonamide
N-4-Chloro-2-(pyridine-3-carbonyl)-phenyl-4-methoxy-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-dimethylamino-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-fluoro-benzenesulfonamide
4-Chloro-N-4-chloro-2-(2-fluoro-benzoyl)-phenyl-benzenesulfonamide
N-4-Chloro-2-(2-fluoro-benzoyl)-phenyl-4-methoxy-benzenesulfonamide
Thiophene-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
5-Bromo-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
5-Chloro-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-4-Chloro-2-(2-fluoro-benzoyl)-phenyl-4-nitro-benzenesulfonamide
N-4-Chloro-2-(2-fluoro-benzoyl)-phenyl-4-methyl-benzenesulfonamide
4-Chloro-N-4-chloro-2-(pyridine-2-carbonyl)-phenyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-benzenesulfonamide
N-4-(2-Benzoyl-4-chloro-phenylsulfamoyl)-phenyl-acetamide
N-4-Chloro-2-(pyridine-2-carbonyl)-phenyl-4-methoxy-benzenesulfonamide
N-4-Chloro-2-(pyridine-2-carbonyl)-phenyl-4-methyl-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-cyano-benzenesulfonamide
4,5-Dibromo-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-4-Chloro-2-(pyridine-3-sulfonyl)-pheny-4-nitro-benzenesulfonamide
Naphthalene-2-sulfonic acid 4-chloro-2-(pyridine-3-carbonyl)-phenyl-amide
N-(2-Benzoyl-4-chloro-phenyl)-3-bromo-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-4-methyl-3-nitro-benzenesulfonamide
N-4-Chloro-2-(2-methoxy-benzoyl)-phenyl-4-nitro-benzenesulfonamide
N-(2-Benzoyl-4-chloro-phenyl)-2-trifluoromethyl-benzenesulfonamide
5-Chloro-3-methyl-benzobthiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-
amide
N-(2-Benzoyl-phenyl)-4-nitro-benzenesulfonamide
5-Isoxazol-3-yl-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-(2-Benzoyl-phenyl)-4-methyl-benzenesulfonamide
Benzobthiophene-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-(4-Chloro-2-phenylsulfanyl-phenyl)-4-isopropoxy-benzenesulfonamide
N-(2-Benzenesulfonyl-4-chloro-phenyl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridine-4-carbonyl)-phenyl-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl-4-isopropoxy-benzenesulfonamide
4-Isopropoxy-N-2-(pyridine-4-carbonyl)-4-trifluoromethyl-phenyl-
benzenesulfonamide
4-Ethoxy-N-2-(pyridine-4-carbonyl)-4-trifluoromethyl-phenyl-benzenesulfonamide
N-5-Chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl-4-isopropyl-benzenesulfonamide
N-5-Chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl-4-isopropoxy-benzenesulfonamide
N-5-Chloro-3-(thiophene-2-carbonyl)-pyridin-2-yl-4-isopropoxy-benzenesulfonamide
5-Oxazol-5-yl-thiophene-2-sulfonic acid 5-chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl-
amide
N-3-(Benzofuran-2-carbonyl)-5-chloro-pyridin-2-yl-4-isopropoxy-
benzenesulfonamide
N-(2-Benzoyl-4-trifluoromethyl-phenyl)-4-isopropoxy-benzenesulfonamide
N-(3-Benzoyl-pyridin-4-yl)-4-isopropoxy-benzenesulfonamide
N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropyl-benzenesulfonamide
N-(3-Benzoyl-5-nitro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide
5-Oxazol-5-yl-thiophene-2-sulfonic acid (3-benzoyl-5-chloro-pyridin-2-yl)-amide
N-(2-Benzoyl-4-chloro-phenyl)-4-isopropylamino-benzenesulfonamide
N-(4-Benzoyl-pyridin-3-yl)-4-isopropyl-benzenesulfonamide
N-(4-Benzoyl-pyridin-3-yl)-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridin-3-yloxy)-phenyl-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-pyridin-3-yl)-4-isopropoxy-benzenesulfonamide
N-3-(3-Fluoro-benzoyl)-pyridin-2-yl-4-isopropoxy-benzenesulfonamide
N-4-Chloro-2-(pyridin-3-yloxy)-phenyl-4-isopropoxy-benzenesulfonamide
4-Isopropoxy-N-3-(pyridine-4-carbonyl)-pyridin-4-yl-benzenesulfonamide
6-Isopropoxy-pyridine-3-sulfonic acid (3-benzoyl-5-chloro-pyridin-2-yl)-amide
6-Isopropoxy-pyridine-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide
N-4-Chloro-2-(pyridin-2-ylsulfanyl)-phenyl-4-isopropyl-benzenesulfonamide
N-(2-Benzoyl-phenyl)-4-isopropoxy-benzenesulfonamide; and pharmaceutically
acceptable salts, solvates, and hydrates thereof.
16. The method of claim 13, wherein the inflammatory disease or condition is Crohn’s disease or colitis.
17. The method of claim 13, wherein the inflammatory disease or condition is Celiac’s disease.
18. The method of claim 13, wherein the compound inhibits the binding of a ligand to CCR9.
19. The method of claim 18, wherein the ligand is TECK.
20. A method of inhibiting CCR9-mediated homing of leukocytes in a subject in need of such treatment comprising administering to the subject an effective amount of at least one compound represented by the following structural formula:
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein:
Y is C(O), S, S(O) or S(O)2;
X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR;
R, for each occurrence, and R1 are each, independently, H or a substituent;
R6 is H, an aliphatic group, an aryl group or an aliphatic carbonyl group;
ring A is substituted or unsubstituted; and
Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
21. The method of claim 20, wherein the compound is represented by a structural formula selected from the group consisting of A, B, C, and D:
A.
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein: R19 and R20 are each, independently, H or a substituent.
B.
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein: R1, R2, R3, R4, R5, and each R are, independently, H, an aliphatic group, haloalkyl, halo, COOH, NO2, alkoxy, or haloalkoxy; and
X4 is CR, N or N+\u2014O\u2212;
C.
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
X4 is CR, N or N+\u2014O\u2212;
R8 is H or an electron withdrawing group;
m and n are each, independently, 0 or an integer from 1 to 3;
each R9 is, independently, an aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, hydroxy, NR11CO2R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R1)2, or NR11C(O)R12; or two adjacent R9 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R10 is, independently, halo, aliphatic group, alkoxy, or haloalkyl; or two adjacent R10 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R11 is, independently, H or an aliphatic group; and
R12 is an aliphatic group; and
D.
or pharmaceutically acceptable salts, solvates or hydrates thereof,
wherein:
R8 is a halo, nitro, alkylcarbonyl or trihaloalkyl;
p is 0 or an integer from 1 to 3; and
each R13 is, independently, a halo, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heteroaryl.
22. A method of inhibiting homing of leukocytes to mucosal tissue in a subject in need of such treatment, comprising adiministering to the subject an effective amount of at least one compound represented by the following structural formula:
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
Y is C(O), S, S(O) or S(O)2;
X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR;
R, for each occurrence, and R1 are each, independently, H or a substituent;
R6 is H, an aliphatic group, an aryl group or an aliphatic carbonyl group;
ring A is substituted or unsubstituted; and
Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of characterizing a plurality of structures of interest on a semiconductor wafer, the method comprising:
measuring a plurality of spectra signals from a particular structure of interest at a plurality of azimuth angles from one or more sensors of a metrology system;
determining a difference spectrum based on the spectra signals obtained for the azimuth angles; and
determining and reporting a quality indication of the particular structure of interest based on analyzing the difference spectrum.
2. The method of claim 1, wherein determining the quality indication of the particular structure is performed without use of a model or extraction of a quantitative feature from such particular structure of interest.
3. The method of claim 1, wherein the difference spectrum is an average difference of a plurality of differences between the spectra signals at the azimuth angles over a plurality of wavelengths.
4. The method of claim 3, wherein the difference spectrum is a highest one of a plurality of differences between the spectra signals at the azimuth angles at a particular one of a plurality of wavelength ranges.
5. The method of claim 3, wherein the particular structure is a grating structure, the method further comprising:
determining theoretical or measured difference spectra for the azimuth angles for a nondefective grating structure; and
normalizing the average difference by the theoretical spectral difference to determine a defect quantity.
6. The method of claim 1, wherein measuring spectra includes generating a differential model by using two dimensional beam profile reflectometry.
7. The method of claim 6, further comprising determining a differential model between an image and best fit of a radially symmetric image with a residual error and determining whether the difference spectra indicate a film or defective structure based on such differential model.
8. The method of claim 1, wherein the targets are selected from Directed Self Assembly (DSA) structures, under layer non-Directed Self Assembly (non-DSA) structures, or patterned resist structures.
9. The method of claim 1, further comprising:
collecting reference data that quantifies pattern defects using a CD SEM tool;
obtaining spectra signals at the azimuth angles from a training set of pattern structures having known pattern defects;
determining a first relation function between spectra signals measured at different azimuth angles and a residual error, wherein the first relationship is based on the spectra signals obtained at the azimuth angles from the training set;
determining a second relation function between a residual error and a quantification of pattern defects based on the reference data; and
inputting the spectra signals measured from the particular structure of interest at the azimuth angles into the second relation function to determine a quantification of pattern defects for such particular structure.
10. The method of claim 9, wherein the first and second relation functions are based on a data reduction technique applied to the spectra signals and residual errors for the training set and the particular structure.
11. A method of characterizing a film of interest on a semiconductor wafer, the method comprising:
at one or more sensors of a metrology system, measuring a plurality of spectra signals from a plurality of neighboring locations at a measurement site of the film or a structure that is designed to be uniform across the measurement site;
determining an average or mean signal of the spectra signals;
determining a standard deviation of each of the spectra signal at each location from the average or mean signal; and
determining and reporting a quality indication for each location of the film or structure based on analyzing the standard deviation for such location without use of a model or extraction of a quantitative feature from the film or structure.
12. A semiconductor metrology system, comprising:
an illuminator for generating illumination;
illumination optics for directing the illumination towards a particular structure at a plurality of azimuth angles;
collection optics for directing a plurality of spectra signals in response to the illumination at the azimuth angles from the particular structure to a sensor;
the sensor for acquiring the plurality of spectra signals from the particular structure for the azimuth angles; and
a processor and memory configured for performing the following operations:
determining a difference spectrum based on the spectra signals obtained for the azimuth angles; and
determining and reporting a quality indication of the particular structure of interest based on analyzing the difference spectrum.
13. The system of claim 12, wherein determining the quality indication of the particular structure is performed without use of a model or extraction of a quantitative feature from such particular structure of interest.
14. The system of claim 12, wherein the difference spectrum is an average difference of a plurality of differences between the spectra signals at the azimuth angles over a plurality of wavelengths.
15. The system of claim 14, wherein the difference spectrum is a highest one of a plurality of differences between the spectra signals at the azimuth angles at a particular one of a plurality of wavelength ranges.
16. The system of claim 14, wherein the particular structure is a grating structure, the processor and memory being configured for:
determining theoretical or measured difference spectra for the azimuth angles for a nondefective grating structure; and
normalizing the average difference by the theoretical spectral difference to determine a defect quantity.
17. The system of claim 12, wherein measuring spectra includes generating a differential model by using two dimensional beam profile reflectometry.
18. The system of claim 17, the processor and memory being configured for determining a difference between the differential model between an image and best fit of a radially symmetric image.
19. The system of claim 12, wherein the targets are selected from Directed Self Assembly (DSA) structures, under layer non-Directed Self Assembly (non-DSA) structures, or patterned resist structures.
20. The system of claim 12, the processor and memory being configured for:
collecting reference data that quantifies pattern defects using a CD SEM tool;
obtaining spectra signals at the azimuth angles from a training set of pattern structures having known pattern defects;
determining a first relation function between spectra signals measured at different azimuth angles and a residual error, wherein the first relationship is based on the spectra signals obtained at the azimuth angles from the training set;
determining a second relation function between a residual error and a quantification of pattern defects based on the reference data; and
inputting the spectra signals measured from the particular structure of interest at the azimuth angles into the second relation function to determine a quantification of pattern defects for such particular structure.
21. The system of claim 20, wherein the first and second relation functions are based on a data reduction technique applied to the spectra signals and residual errors for the training set and the particular structure.